SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-056311
Filing Date
2024-05-09
Accepted
2024-05-09 08:32:42
Documents
43
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q labp-20240331.htm   iXBRL 10-Q 860452
2 EX-31.1 labp-ex31_1.htm EX-31.1 19760
3 EX-32.1 labp-ex32_1.htm EX-32.1 11750
  Complete submission text file 0000950170-24-056311.txt   4131262

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT labp-20240331.xsd EX-101.SCH 811362
46 EXTRACTED XBRL INSTANCE DOCUMENT labp-20240331_htm.xml XML 503777
Mailing Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060
Business Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060 540-818-2844
Landos Biopharma, Inc. (Filer) CIK: 0001785345 (see all company filings)

IRS No.: 815085535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39971 | Film No.: 24928761
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)